Hcw biologics announces pricing of $5.0 million follow-on offering priced at-the-market under nasdaq rules

Miramar, fla., may 13, 2025 (globe newswire) -- hcw biologics inc. (the “company”), (nasdaq: hcwb), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced the pricing of its follow-on offering of an aggregate of 671,140 units at a purchase price of $7.45 per unit priced at-the-market under nasdaq rules.
HCWB Ratings Summary
HCWB Quant Ranking